Filing Details

Accession Number:
0001209191-17-055360
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-03 18:06:56
Reporting Period:
2017-10-02
Accepted Time:
2017-10-03 18:06:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
906709 Nektar Therapeutics NKTR Pharmaceutical Preparations (2834) 943134940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1394875 M Gil Labrucherie C/O Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco CA 94158
Svp & Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-10-02 120,000 $11.34 183,414 No 4 M Direct
Common Stock Disposition 2017-10-02 120,000 $24.45 63,414 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2017-10-02 120,000 $0.00 120,000 $11.34
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-02-01 2018-01-31 No 4 M Direct
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on May 22, 2017 related to 120,000 stock options scheduled to expire on January 31, 2018.
  2. This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
  3. This transaction was executed in multiple trades at prices ranging from $23.99 to $24.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.